IVRS appointed as industry winners 2022!
IVRS was recently appointed as industry winners or ‘’Branschvinnare’’, which is awarded to Swedish companies who have reached exceedingly positive revenue and result changes during the year. See what our CEO, Ramin Massoumi, had to say on the matter: Our mission has always been to bridge the gap between preclinical and clinical studies by offering flexible projects by […]
New segment model on human breast cancer for preclinical drug validation!
We constantly work to develop clinically relevant models to provide reliable platforms for preclinical drug validation. Today, we are thrilled to announce the launch of our second segment model on human breast cancer, using orthotopic transplantation of patient-derived xenografts (PDX) and in vivo bioluminescence imaging. All of these essential components are conducted in-house, ensuring seamless […]
IVRS is launching a segment model on human pancreatic cancer!
Introducing our pancreatic cancer segment model. At IVRS AB we are constantly working on ways to expand our service array with robust and clinically relevant methods. We are thus proud to introduce a series of segment models, starting with our platform to validate drug candidates targeting pancreatic cancer. Our approach to a successful validatory study combines orthotopic […]
IVRS joined Science Exchange and scientist.com
IVRS has joined Science Exchange and scientist.com network for establishing new business opportunities with R&D organizations who have an immediate need for the service.
